## Sophie Hillion

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4001742/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular Mechanisms Driving IL-10- Producing B Cells Functions: STAT3 and c-MAF as Underestimated Central Key Regulators?. Frontiers in Immunology, 2022, 13, 818814.	2.2	8
2	Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study. Journal of Cystic Fibrosis, 2022, 21, 529-536.	0.3	6
3	The diversity of the plasmablast signature across species and experimental conditions: A metaâ€analysis. Immunology, 2021, 164, 120-134.	2.0	3
4	Abatacept Promotes Regulatory B Cell Functions, Enhancing Their Ability to Reduce the Th1 Response in Rheumatoid Arthritis Patients through the Production of IL-10 and TGF-β. Journal of Immunology, 2021, 207, 470-482.	0.4	7
5	A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases. Arthritis and Rheumatology, 2021, 73, 1550-1561.	2.9	24
6	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	2.3	7
7	Complement System: a Neglected Pathway in Immunotherapy. Clinical Reviews in Allergy and Immunology, 2020, 58, 155-171.	2.9	29
8	The Innate Part of the Adaptive Immune System. Clinical Reviews in Allergy and Immunology, 2020, 58, 151-154.	2.9	52
9	Innate B Cells: the Archetype of Protective Immune Cells. Clinical Reviews in Allergy and Immunology, 2020, 58, 92-106.	2.9	30
10	The regulatory capacity of B cells directs the aggressiveness of CLL. OncoImmunology, 2019, 8, 1554968.	2.1	4
11	Association of Defective Regulation of Autoreactive Interleukinâ€6–Producing Transitional B Lymphocytes WithÂDisease in Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 450-461.	2.9	33
12	Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies. Clinical Immunology, 2018, 194, 92-99.	1.4	6
13	Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?. Clinical Reviews in Allergy and Immunology, 2017, 53, 219-236.	2.9	36
14	Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up. Clinical Reviews in Allergy and Immunology, 2017, 53, 14-27.	2.9	22
15	Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion. European Journal of Haematology, 2016, 96, 229-235.	1.1	14
16	In-depth characterization of CD24 high CD38 high transitional human BÂcells reveals different regulatory profiles. Journal of Allergy and Clinical Immunology, 2016, 137, 1577-1584.e10.	1.5	88
17	Review: Intravenous Immunoglobulin and B Cells: When the Product Regulates the Producer. Arthritis and Rheumatology, 2015, 67, 595-603.	2.9	17
18	Regulatory B Cells: An Exciting Target for Future Therapeutics in Transplantation. Frontiers in Immunology, 2014, 5, 11.	2.2	44

SOPHIE HILLION

#	Article	IF	CITATIONS
19	Diagnostic criteria for autoimmune neutropenia. Autoimmunity Reviews, 2014, 13, 574-576.	2.5	26
20	B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody–mediated rejection. Kidney International, 2014, 85, 590-599.	2.6	62
21	Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. Journal of Allergy and Clinical Immunology, 2014, 133, 181-188.e9.	1.5	49
22	A5.20â€Intravenous Immunoglobulin Induces Functionnal Silencing in Human B Lymphocytes. Annals of the Rheumatic Diseases, 2013, 72, A37.3-A38.	0.5	0
23	Appraisal of IgM Kappa/IgM Lambda Variations Using HevyLite® After Rituximab As Consolidation Therapy in Patients with Waldenstrol îm's Macroglobulinemia. Blood, 2012, 120, 4879-4879.	0.6	0
24	TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. Journal of Autoimmunity, 2011, 37, 190-197.	3.0	40
25	Autoantibodies to Endothelial Cell Surface ATP Synthase, the Endogenous Receptor for Hsp60, Might Play a Pathogenic Role in Vasculatides. PLoS ONE, 2011, 6, e14654.	1.1	39
26	Intravenous immunoglobulin inhibits toll-like receptor 9-induced activation of auto-reactive B lymphocytes. Annals of the Rheumatic Diseases, 2011, 70, A61-A61.	0.5	0
27	CD5 Promotes IL-10 Production in Chronic Lymphocytic Leukemia B Cells through STAT3 and NFAT2 Activation. Journal of Immunology, 2011, 186, 4835-4844.	0.4	65
28	Etiopathogenic Role of B Cells in Primary Sjögren's Syndrome. , 2011, , 67-82.		0
29	IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood, 2010, 116, 1698-1704.	0.6	151
30	The Fmsâ€like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sj¶gren's syndrome. Arthritis and Rheumatism, 2010, 62, 3447-3456.	6.7	55
31	Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney International, 2010, 78, 503-513.	2.6	249
32	Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome. Journal of Autoimmunity, 2010, 35, 336-341.	3.0	41
33	Signaling pathways regulating RAG expression in B lymphocytes. Autoimmunity Reviews, 2009, 8, 599-604.	2.5	10
34	Transmembrane BAFF from rheumatoid synoviocytes requires interleukinâ€6 to induce the expression of recombinationâ€activating gene in B lymphocytes. Arthritis and Rheumatism, 2009, 60, 1261-1271.	6.7	26
35	Blood CD8 <sup>+</sup> T cell responses against myelin determinants in multiple sclerosis and healthy individuals. European Journal of Immunology, 2008, 38, 1889-1899.	1.6	47
36	What is the contents of the magic draft IVIg?. Autoimmunity Reviews, 2008, 7, 435-439.	2.5	124

SOPHIE HILLION

#	Article	IF	CITATIONS
37	Autoimmune Neutropenia. , 2008, , 539-541.		0
38	Autoimmune Lymphopenia. , 2008, , 535-538.		0
39	IL-6 Contributes to the Expression of RAGs in Human Mature B Cells. Journal of Immunology, 2007, 179, 6790-6798.	0.4	33
40	Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus. Immunology, 2007, 122, 371-380.	2.0	33
41	Peripheral expression of RAG in human B lymphocytes in normal and pathological conditions is dependent on interleukin-6. Autoimmunity Reviews, 2007, 6, 415-420.	2.5	14
42	RAG-mediated secondary rearrangements of B-cell antigen receptors in rheumatoid synovial tissue. Autoimmunity Reviews, 2007, 7, 155-159.	2.5	14
43	B lymphocytes on the front line of autoimmunity. Autoimmunity Reviews, 2006, 5, 215-221.	2.5	42
44	An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood, 2005, 106, 2781-2789.	0.6	64
45	Expression and Reexpression of Recombination Activating Genes: Relevance to the Development of Autoimmune States. Annals of the New York Academy of Sciences, 2005, 1050, 10-18.	1.8	23
46	Expression of RAGs in Peripheral B Cells outside Germinal Centers Is Associated with the Expression of CD5. Journal of Immunology, 2005, 174, 5553-5561.	0.4	45
47	Dual Response to IL-21 and IFN-Alpha Reveals Human B-Cell Precursors With Multiple Differentiation Potentials. SSRN Electronic Journal, 0, , .	0.4	0
48	A Pathogenic Cytokine Network Is Associated with Pro-Inflammatory B Cells in Systemic Lupus Erythematosus Patients. SSRN Electronic Journal, 0, , .	0.4	1